Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
AN ANIP ANI PHARMACEUTICALS INC FY ended Dec 31, 2025 | $72.83 | $1.64B | $2.20B | $883.37M | $187.66M | $78.34M | 21.94x | 1.85x | 10.07x |
VN VNDA Vanda Pharmaceuticals Inc. FY ended Feb 05, 2026 | $5.29 | $319.85M | $212.27M | $216.11M | -$130.54M | -$220.47M | -1.41x | 1.48x | — |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.98x | 4/5 | $1.63B | $28.03 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 2.90x | 5/5 | $2.09B | $35.91 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 2.50x | 5/5 | -$96.53M | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
JA JAZZ Jazz Pharmaceuticals plc FY ended Apr 15, 2026 | $244.54 | $15.87B | $18.75B | $4.27B | $69.38M | -$356.15M | -41.87x | 3.72x | 58.20x |
IN INCY INCYTE CORP FY ended Feb 03, 2026 | $124.37 | $24.85B | $22.95B | $5.14B | $1.76B | $1.29B | 19.40x | 4.83x | 13.04x |
AN ANIP ANI PHARMACEUTICALS INC FY ended Dec 31, 2025 | $72.83 | $1.64B | $2.20B | $883.37M | $187.66M | $78.34M | 21.94x | 1.85x | 10.07x |
VN VNDA Vanda Pharmaceuticals Inc. FY ended Feb 05, 2026 | $5.29 | $319.85M | $212.27M | $216.11M | -$130.54M | -$220.47M | -1.41x | 1.48x | — |
HR HRMY Harmony Biosciences Holdings, Inc. FY ended Feb 20, 2026 | $39.21 | $2.28B | $1.90B | $868.45M | $262.93M | $158.69M | 14.47x | 2.63x | 6.82x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.98x | 4/5 | $1.63B | $28.03 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 2.90x | 5/5 | $2.09B | $35.91 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 2.50x | 5/5 | -$96.53M | — | Target fundamentals do not produce a usable positive equity value. |
